EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
5.05
-0.37 (-6.83%)
At close: Apr 1, 2025, 4:00 PM
5.28
+0.23 (4.53%)
After-hours: Apr 1, 2025, 4:26 PM EDT
EyePoint Pharmaceuticals Revenue
In the year 2024, EyePoint Pharmaceuticals had annual revenue of $43.27M, down -5.97%. EyePoint Pharmaceuticals had revenue of $11.59M in the quarter ending December 31, 2024, a decrease of -17.39%.
Revenue (ttm)
$43.27M
Revenue Growth
-5.97%
P/S Ratio
7.05
Revenue / Employee
$262,261
Employees
165
Market Cap
347.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EYPT News
- 5 days ago - EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewsWire
- 15 days ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 4 weeks ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 - GlobeNewsWire
- 5 weeks ago - EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival - Seeking Alpha